Harpoon Therapeutics Presents Interim Clinical Data from its Ongoing Phase 1/2 Study and New…
Encouraging clinical activity in higher dose cohorts with 63% ORR and 88% DCR reported in 2150 µg/week cohort with 8 disease evaluable patients with relapsed/refractory multiple myeloma Tolerable safety profile with cytokine release…